A Paradigm Shift in Sepsis Diagnostics

Technology Networks

By Anna MacDonald of Technology Networks Immunexpress is advancing next-generation clinical sepsis diagnosis tests for use in emergency room and intensive care unit settings. The company’s lead test SeptiCyte® RAPID is clinically validated and has received 510(k) FDA clearance indicated for the diagnosis of sepsis in adults. It is the first gene expression host response…

Read More

Immunexpress Announces the Launch of New SeptiCyte RAPID® CE-IVD EDTA Blood Compatible Cartridges

Immunexpress - the signature diagnostics for sepsis

SEATTLE, Aug. 23, 2022 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the launch of new SeptiCyte RAPID® EDTA blood compatible cartridges for the European market. The updated SeptiCyte® RAPID CE-IVD cartridge adds undiluted EDTA blood as a validated sample type, representing a significant development milestone for…

Read More